Aridis Pharmaceuticals announced the Cystic Fibrosis Foundation invested $4.85M in Aridis common stock on market terms under NASDAQ rules to support the ongoing development of AR-501, an inhalable broad-spectrum anti-infective currently under development for controlling debilitating chronic lung infections in cystic fibrosis patients. Including this funding, the CF Foundation has provided a total of $12.5M in support. Enrollment for a Phase 2a study of AR-501 in CF patients was completed in November 2022. The company anticipates reporting top-line results from its Phase 2a study in the first quarter of 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARDS:
- (Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
- Aridis signs deal for commercial licenses for pan-Ebola, pan-Marburg programs
- Aridis Pharmaceuticals closes patient enrollment in Phase 2a study of AR-501
- Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases
- Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update